SFA Therapeutics Strengthens Intellectual Property in Autoimmune Disease and Hepatocellular Carcinoma
Hand-out
Press Releases
SFA Therapeutics, Inc.  
October 22, 2024

SFA Therapeutics Strengthens Intellectual Property in Autoimmune Disease and Hepatocellular Carcinoma

JENKINTOWN, Pa., Oct. 22, 2024 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory diseases, today announced the expansion of

avatar profile Olean Times Herald

Olean Times Herald


Local & Social